FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386047456> ?p ?o ?g. }

• W4386047456 abstract "To determine the updated long-term outcomes of the Addition of Ovarian Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Regain Vaginal Bleeding After Chemotherapy (ASTRRA) trial.This study is a post-trial follow-up of the ASTRRA trial, involving 1,483 premenopausal women younger than 45 years treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy for estrogen receptor-positive breast cancer. Patients were randomly assigned in a 1:1 ratio to complete 5 years of tamoxifen (TAM) alone (TAM-only) or 5 years of TAM with ovarian function suppression (OFS) for 2 years (TAM + OFS). The primary end point was disease-free survival (DFS), and the secondary end point was overall survival (OS).At 106.4 months of median follow-up, there was a continuous significant reduction in the DFS event rate in the TAM + OFS group. The 8-year DFS rate was 85.4% in the TAM + OFS group and 80.2% in the TAM-only group (hazard ratio [HR], 0.67; 95% CI, 0.51 to 0.87). There were no significant differences in OS between the two groups. The OS rate was 96.5% in the TAM + OFS group and 95.3% in the TAM-only group (HR, 0.78; 95% CI, 0.49 to 1.25).Adding OFS for 2 years to adjuvant TAM with a longer follow-up resulted in consistent DFS benefits, suggesting that adding OFS to TAM should be considered for patients who remain in a premenopausal state or resume ovarian function after chemotherapy." @default.
• W4386047456 created "2023-08-23" @default.
• W4386047456 creator A5009098657 @default.
• W4386047456 creator A5010796867 @default.
• W4386047456 creator A5012058954 @default.
• W4386047456 creator A5013544822 @default.
• W4386047456 creator A5016181266 @default.
• W4386047456 creator A5021046796 @default.
• W4386047456 creator A5027653488 @default.
• W4386047456 creator A5028906808 @default.
• W4386047456 creator A5031863352 @default.
• W4386047456 creator A5032135404 @default.
• W4386047456 creator A5033852351 @default.
• W4386047456 creator A5036460484 @default.
• W4386047456 creator A5040393015 @default.
• W4386047456 creator A5041704574 @default.
• W4386047456 creator A5058254590 @default.
• W4386047456 creator A5070517482 @default.
• W4386047456 creator A5072503728 @default.
• W4386047456 creator A5081798094 @default.
• W4386047456 creator A5082400192 @default.
• W4386047456 creator A5085180691 @default.
• W4386047456 date "2023-08-22" @default.
• W4386047456 modified "2023-10-10" @default.
• W4386047456 title "Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor–Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial" @default.
• W4386047456 cites W1964291161 @default.
• W4386047456 cites W1964979154 @default.
• W4386047456 cites W2003819085 @default.
• W4386047456 cites W2084741580 @default.
• W4386047456 cites W2097966128 @default.
• W4386047456 cites W2118696602 @default.
• W4386047456 cites W2128936801 @default.
• W4386047456 cites W2169649287 @default.
• W4386047456 cites W2283559195 @default.
• W4386047456 cites W2333641069 @default.
• W4386047456 cites W2343407300 @default.
• W4386047456 cites W2405981651 @default.
• W4386047456 cites W2783922985 @default.
• W4386047456 cites W2802421801 @default.
• W4386047456 cites W2806866264 @default.
• W4386047456 cites W2807161544 @default.
• W4386047456 cites W2972559819 @default.
• W4386047456 cites W2980534320 @default.
• W4386047456 cites W3163945082 @default.
• W4386047456 cites W4289778745 @default.
• W4386047456 cites W4311018682 @default.
• W4386047456 doi "https://doi.org/10.1200/jco.23.00557" @default.
• W4386047456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37607321" @default.
• W4386047456 hasPublicationYear "2023" @default.
• W4386047456 type Work @default.
• W4386047456 citedByCount "0" @default.
• W4386047456 crossrefType "journal-article" @default.
• W4386047456 hasAuthorship W4386047456A5009098657 @default.
• W4386047456 hasAuthorship W4386047456A5010796867 @default.
• W4386047456 hasAuthorship W4386047456A5012058954 @default.
• W4386047456 hasAuthorship W4386047456A5013544822 @default.
• W4386047456 hasAuthorship W4386047456A5016181266 @default.
• W4386047456 hasAuthorship W4386047456A5021046796 @default.
• W4386047456 hasAuthorship W4386047456A5027653488 @default.
• W4386047456 hasAuthorship W4386047456A5028906808 @default.
• W4386047456 hasAuthorship W4386047456A5031863352 @default.
• W4386047456 hasAuthorship W4386047456A5032135404 @default.
• W4386047456 hasAuthorship W4386047456A5033852351 @default.
• W4386047456 hasAuthorship W4386047456A5036460484 @default.
• W4386047456 hasAuthorship W4386047456A5040393015 @default.
• W4386047456 hasAuthorship W4386047456A5041704574 @default.
• W4386047456 hasAuthorship W4386047456A5058254590 @default.
• W4386047456 hasAuthorship W4386047456A5070517482 @default.
• W4386047456 hasAuthorship W4386047456A5072503728 @default.
• W4386047456 hasAuthorship W4386047456A5081798094 @default.
• W4386047456 hasAuthorship W4386047456A5082400192 @default.
• W4386047456 hasAuthorship W4386047456A5085180691 @default.
• W4386047456 hasConcept C121608353 @default.
• W4386047456 hasConcept C126322002 @default.
• W4386047456 hasConcept C143998085 @default.
• W4386047456 hasConcept C168563851 @default.
• W4386047456 hasConcept C207103383 @default.
• W4386047456 hasConcept C2776694085 @default.
• W4386047456 hasConcept C2777176818 @default.
• W4386047456 hasConcept C2777863537 @default.
• W4386047456 hasConcept C29456083 @default.
• W4386047456 hasConcept C44249647 @default.
• W4386047456 hasConcept C530470458 @default.
• W4386047456 hasConcept C71924100 @default.
• W4386047456 hasConcept C84606932 @default.
• W4386047456 hasConceptScore W4386047456C121608353 @default.
• W4386047456 hasConceptScore W4386047456C126322002 @default.
• W4386047456 hasConceptScore W4386047456C143998085 @default.
• W4386047456 hasConceptScore W4386047456C168563851 @default.
• W4386047456 hasConceptScore W4386047456C207103383 @default.
• W4386047456 hasConceptScore W4386047456C2776694085 @default.
• W4386047456 hasConceptScore W4386047456C2777176818 @default.
• W4386047456 hasConceptScore W4386047456C2777863537 @default.
• W4386047456 hasConceptScore W4386047456C29456083 @default.
• W4386047456 hasConceptScore W4386047456C44249647 @default.
• W4386047456 hasConceptScore W4386047456C530470458 @default.
• W4386047456 hasConceptScore W4386047456C71924100 @default.
• W4386047456 hasConceptScore W4386047456C84606932 @default.
• W4386047456 hasLocation W43860474561 @default.
• W4386047456 hasLocation W43860474562 @default.

• next